Eli Lilly’s weight-loss drug Zepbound might help cure your sleep apnea

The drug demonstrated effectiveness in reducing the severity of obstructive sleep apnea in patients with obesity, outperforming a placebo.

Eli Lilly and Company announced promising results for its weight loss drug Zepbound, indicating its potential as a treatment for sleep apnea. The drug demonstrated effectiveness in reducing the severity of obstructive sleep apnea in patients with obesity, outperforming a placebo in two late-stage clinical trials.